SOURCE-LINKED STUDY SUMMARY
Mechanism of Kushen Tongguan Pill on benign prostatic hyperplasia: roles of TLR4/NF-κB pathway and macrophage M1 polarization.
Abstract summarizedQuality not appraised
- What was studied
- A preclinical study tested Kushen Tongguan Pill in testosterone-propionate-induced benign prostatic hyperplasia and examined inflammatory signaling.
- Who / model studied
- The in vivo work used a rat BPH model induced by castration and testosterone propionate.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- KSTG dose-dependently reduced prostate size measures and several inflammatory markers in the rat model.
- Limitations & context
- Evidence was limited to animal and cell models, so the abstract does not demonstrate efficacy or safety in humans.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1007/s10735-026-10945-6